Based on the COCIS meta-analysis of carboplatin versus cisplatin-based chemotherapy of SCLC which included patients getting radiotherapy for limited-stage disease (Rossi et al, JCO 2012), there was no evident survival advantage with cisplatin overall. In multivariate analysis, there appears to be tr...

Generally the preference is to use Cisplatin over Carboplatin for the curative intent concurrent chemoRT in LD-SCLC. The exception can primarily be in toxicity consideration esp. in renal, CHF and hearing toxicities in patients who already have these organ dysfunction at baseline, elderly or frail p...

Only if there is a good reason not to use cisplatin, such as in patients with renal insufficiency or heart failure.

My preference is cisplatin plus etoposide, but when cisplatin-ineligible (or if cisplatin is poorly tolerated), carboplatin is perfectly reasonable and supported by retrospective outcomes data. No need to be too dogmatic in my opinion.